Abstract 1538P
Background
Neoadjuvant chemoimmunotherapy might benefit pts with locally advanced oesophageal squamous cell carcinoma (ESCC). Herein, we aimed to evaluate the efficacy and safety of Tislelizumab (a humanized anti-PD-1 antibody) combined with cisplatin plus albumin-paclitaxel(nab-PTX)/paclitaxel (PTX).
Methods
A prospective, open, single-arm, two-cohort phase II trial was conducted. ESCC Pts with resectable locally advanced disease were enrolled and randomly allocated into group nab-PTX (group A) or group PTX (group B). Pts received intravenous Tislelizumab (200 mg, day 1) combined with cisplatin (25mg/m2, day 1-3) plus nab-PTX (130 mg/m2, day 1, 8) in group A or PTX (75 mg/m2, day 1, 8) in group B of each 21-day cycle for two cycles before surgery, respectively. The primary endpoint was major pathologic responses (MPR) rate. The Secondary endpoints were pathological complete response (pCR) rate, R0 resection rate, treatment related adverse events (TRAEs), DFS and OS.
Results
From Feb 14, 2022, to Mar 8, 2023, 39 pts were enrolled (n=20 in group A, n=19 in group B). 35 pts received the full two-cycle chemoimmunotherapy successfully and received surgery (n=19 in group A, n=16 in group B), 2 pts in group B didn't receive the second cycle due to intolerance and dropped out, and 2 patients gave up surgery after neoadjuvant therapy for personal reasons (n=1 in each group). Pts underwent surgery within 23-97 days (median 35 days) after neoadjuvant treatment, among others, 2 pts delayed surgery due to TRAEs. All patients achieved radical (R0) resection. No patient died during neoadjuvant therapy and perioperative period. In group A, the MPR rate and pCR rate were 78.9% (15/19) and 36.8% (7/19), respectively. In group B, the MPR rate and pCR rate were 18.8% (3/16) and 0% (0/16), respectively. The most common TRAEs were lymphopenia (45.7%), diarrhoea (34.3.0%) and fatigue (31.4%), and there was no significant difference between groups.
Conclusions
Neoadjuvant treatment with Tislelizumab combined with cisplatin plus nab-PTX demonstrated promising anti-tumor efficacy with acceptable toxicity in pts with locally advanced thoracic ESCC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Y. Sun.
Funding
BeiGene Pharmaceutical (Shanghai) Co., Ltd.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1564P - Gut microbiome and metabolome are associated with the response to chemoradiotherapy in patients with esophageal cancer
Presenter: Mingqiang Lin
Session: Poster session 21
1565P - ERCC1 gene polymorphism influences overall survival in early oesophageal cancer: Results from the phase III MRC OEO2 randomised controlled trial
Presenter: Georgina Keogh
Session: Poster session 21
1566P - Clinical relevance of circulating tumor DNA in HER2 -positive advanced gastric cancer: Results from phase Ib trial of HER2 and PD-1 dual targeted therapy (Ni-High)
Presenter: Hiroki Osumi
Session: Poster session 21
1567P - The effect of SGLT2i and DPP4i on new-onset gastric cancer and gastric diseases in type 2 diabetes mellitus: A population-based cohort study
Presenter: Hou In Chou
Session: Poster session 21
1568P - Establishment of a platform to predict radiation sensitivity in organoids derived from esophageal cancer patients
Presenter: Ga Yeon Kim
Session: Poster session 21